Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Cited by (1,034)

Items 201–300 of 1,034

1. Live imaging of SARS-CoV-2 infection in mice reveals neutralizing antibodies require Fc function for optimal efficacy
   Irfan Ullah, Jérémie Prévost, M. Ladinsky, H. Stone, Mao-Lin Lu, S. Anand, G. Beaudoin-Bussières, K. Symmes, M. Benlarbi, Shi-Lei Ding et al. · 2021 · bioRxiv
2. Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain
   Tan, Timothy J. C., Yuan, Meng, Kuzelka, Kaylee, Padron, Gilberto C., Beal, Jacob R., Chen, Xin, Wang, Yiquan, Rivera-Cardona, Joel, Zhu, Xueyong, Stadtmueller, Beth M. et al. · 2021 · Nature Communications
3. A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo
   L. Hanke, H. Das, D. Sheward, Laura Perez Vidakovics, E. Urgard, Ainhoa Moliner-Morro, Changil Kim, V. Karl, A. Pankow, Natalie L. Smith et al. · 2022 · Nature Communications
4. Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques
   Hyon-Xhi Tan, J. Juno, W. Lee, Isaac M. Barber-Axthelm, Hannah G. Kelly, Kathleen M. Wragg, R. Esterbauer, Thakshila H. Amarasena, F. Mordant, K. Subbarao et al. · 2021 · Nature Communications
5. SARS-CoV-2 RBD-Tetanus toxoid conjugate vaccine induces a strong neutralizing immunity in preclinical studies
   Y. Valdés-Balbín, Darielys Santana-Mederos, Lauren Quintero, S. Fernandez, Laura Rodriguez, Belinda Sánchez-Ramírez, Rocmira Perez-Nicado, Claudia Acosta, Y. Méndez, M. G. Ricardo et al. · 2021 · bioRxiv
6. Stereotypic neutralizing VH antibodies against SARS-CoV-2 spike protein receptor binding domain in patients with COVID-19 and healthy individuals
   Sang Il Kim, Jinsung Noh, Sujeong Kim, Younggeun Choi, Duck Kyun Yoo, Yonghee Lee, Hyunho Lee, Jongtak Jung, C. K. Kang, K. Song et al. · 2021 · Science Translational Medicine
7. Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS-CoV-2 vaccine candidates in the Syrian hamster model
   Mohandas, Sreelekshmy, Yadav, Pragya D., Shete-Aich, Anita, Abraham, Priya, Vadrevu, Krishna Mohan, Sapkal, Gajanan, Mote, Chandrashekhar, Nyayanit, Dimpal, Gupta, Nivedita, Srinivas, Vellimedu Kannappa et al. · 2021 · iScience
8. Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies
   L. Kozlovskaya, A. Piniaeva, G. Ignatyev, I. Gordeychuk, V. Volok, Y. V. Rogova, A. Shishova, A. Kovpak, Y. Ivin, L. Antonova et al. · 2021 · Emerging Microbes and Infections
9. Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval
   Ebenezer Tumban · 2020 · Viruses
10. A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants
    Schmitz, Aaron J., Turner, Jackson S., Liu, Zhuoming, Aziati, Ishmael D., Chen, Rita E., Joshi, Astha, Bricker, Traci L., Darling, Tamarand L., Adelsberg, Daniel C., Alsoussi, Wafaa B. et al. · 2021
11. Identification of a therapeutic interfering particle—A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance
    S. Chaturvedi, Gustavo Vasen, M. Pablo, Xinyue Chen, N. Beutler, Arjun J. Kumar, Elizabeth J. Tanner, S. Illouz, Donna Rahgoshay, John C. Burnett et al. · 2021 · Cell
12. A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy
    Allison J. Greaney, Tyler N. Starr, Rachel T. Eguia, Andrea N. Loes, K. Khan, Farina Karim, S. Cele, J. Bowen, Jennifer K. Logue, D. Corti et al. · 2021 · bioRxiv
13. A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates
    P. Weidenbacher, M. Sanyal, N. Friedland, Shao-Geng Tang, Prabhu S. Arunachalam, Meng-Yun Hu, Ozan S. Kumru, M. Morris, J. Fontenot, Lisa M. Shirreff et al. · 2022 · bioRxiv
14. SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns
    Henning Gruell, Kanika Vanshylla, Michael Korenkov, Pinkus Tober‐Lau, Matthias Zehner, Friederike Münn, Hanna Janicki, Max Augustin, Philipp Schommers, Leif Erik Sander et al. · 2022 · Cell Host & Microbe
15. Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class
    Micah Rapp, Yicheng Guo, Eswar R. Reddem, Jian Yu, Lihong Liu, Pengfei Wang, Gabriele Cerutti, Phinikoula S. Katsamba, Jude Saber Bimela, Fabiana A. Bahna et al. · 2021 · Cell Reports
16. Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
    Cherrelle Dacon, Linghang Peng, Ting-Hui Lin, Courtney Tucker, Chang-Chun David Lee, Yu Cong, Lingshu Wang, Lauren Purser, Andrew J. R. Cooper, Jazmean K. Williams et al. · 2022 · Cell Host & Microbe
17. The role of B cells in COVID-19 infection and vaccination
    Shiru Chen, Fei Guan, Fabio Candotti, Kamel Benlagha, Niels Olsen Saraiva Câmara, Andrés A. Herrada, Louisa Katherine James, Jiahui Lei, Heather Miller, Masato Kubo et al. · 2022 · Frontiers in Immunology
18. Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies
    M. Finkelstein, Adam G. Mermelstein, Emma Parker Miller, P. Seth, Erik-Stephane D. Stancofski, D. Fera · 2021 · Viruses
19. A global picture: therapeutic perspectives for COVID-19
    V. Chavda, C. Kapadia, Shailvi Soni, R. Prajapati, S. Chauhan, M. Yallapu, V. Apostolopoulos · 2022 · Immunotherapy
20. Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations
    V. Dussupt, R. Sankhala, Letzibeth Mendez-Rivera, Samantha M. Townsley, Fabian Schmidt, L. Wieczorek, Kerri G. Lal, G. Donofrio, Ursula Tran, Nathaniel D. Jackson et al. · 2021 · Nature Immunology
21. The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants
    Chang Liu, Da-Ming Zhou, Rungtiwa Nutalai, H. Duyvesteyn, Aekkachai Tuekprakhon, H. Ginn, W. Dejnirattisai, P. Supasa, A. Mentzer, Bei-Bei Wang et al. · 2021 · Cell Host and Microbe
22. Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions
    Andrea R. Shiakolas, Kevin J. Kramer, D. Wrapp, S. Richardson, A. Schäfer, Steven J. Wall, Nian-Shuang Wang, Katarzyna Janowska, Kelsey A. Pilewski, R. Venkat et al. · 2021 · Cell Reports Medicine
23. Challenges and developments in universal vaccine design against SARS-CoV-2 variants
    Fangxin Zhao, Xiaodong Zai, Zhiling Zhang, Junjie Xu, Wei Chen · 2022 · npj Vaccines
24. Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain
    Gabriele Cerutti, Yicheng Guo, Pengfei Wang, Manoj S. Nair, Maple Wang, Yaoxing Huang, Jian Yu, Lihong Liu, Phinikoula S. Katsamba, Fabiana A. Bahna et al. · 2021 · Cell Reports
25. Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates
    J. Francica, Barbara Flynn, K. Foulds, Amy T. Noe, Anne P. Werner, Ian N. Moore, M. Gagne, T. Johnston, C. Tucker, Rachel L. Davis et al. · 2021 · Science Translational Medicine
26. Animal models for SARS-CoV-2
    Chung-Young Lee, Anice C. Lowen · 2021 · Current Opinion in Virology
27. Breadth and function of antibody response to acute SARS-CoV-2 infection in humans
    Kuan-Ying A. Huang, T. Tan, Ting-Hua Chen, Chung-Guei Huang, R. Harvey, S. Hussain, Cheng-Pin Chen, Adam C. Harding, J. Gilbert-Jaramillo, Xu Liu et al. · 2021 · PLoS Pathogens
28. BNT162b2 vaccine induces divergent B cell responses to SARS-CoV-2 S1 and S2
    R. Brewer, N. Ramadoss, L. Lahey, Shaghayegh Jahanbani, W. Robinson, Tobias V. Lanz · 2021 · Nature Immunology
29. Potent Neutralization of SARS-CoV-2 by Hetero-Bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain
    Huan Ma, Weihong Zeng, Xiang-Zhi Meng, Xiaoxue Huang, Yunru Yang, Dan Zhao, Peigen Zhou, Xiao-Fang Wang, Chang-Cheng Zhao, Yong-Jun Sun et al. · 2021 · Journal of Virology
30. Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2
    Cyril Planchais, Ignacio Fernández, Timothée Bruel, Guilherme Dias de Melo, Matthieu Prot, Maxime Beretta, Pablo Guardado‐Calvo, Jérémy Dufloo, Luis Manuel Molinos-Albert, Marija Backović et al. · 2022 · The Journal of Experimental Medicine
31. A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection
    Naoko Iwata‐Yoshikawa, Nozomi Shiwa, Tsuyoshi Sekizuka, Kaori Sano, Akira Ainai, Takuya Hemmi, Michiyo Kataoka, Makoto Kuroda, Hideki Hasegawa, Tadaki Suzuki et al. · 2022 · Science Advances
32. Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape
    Fred D. Mast, Peter C. Fridy, Natalia E. Ketaren, Junjie Wang, Erica Y. Jacobs, J. P. Olivier, Tanmoy Sanyal, K. Molloy, Fabian Schmidt, Magda Rutkowska et al. · 2021 · eLife
33. The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates
    Da-Peng Li, R. Edwards, K. Manne, David R. Martinez, A. Schäfer, S. Alam, K. Wiehe, Xiao-Zhi Lu, Robert Parks, Laura L. Sutherland et al. · 2021 · bioRxiv
34. Evolution of enhanced innate immune suppression by SARS-CoV-2 Omicron subvariants
    Ann-Kathrin Reuschl, Lucy G. Thorne, M. Whelan, Roberta Ragazzini, Wilhelm Furnon, Vanessa M. Cowton, G. De Lorenzo, Dejan Mesner, Jane Turner, Giulia Dowgier et al. · 2023 · bioRxiv
35. Evolution of antibody immunity following Omicron BA.1 breakthrough infection
    Chengzi I. Kaku, Tyler N. Starr, Pan-Pan Zhou, Haley L. Dugan, Paul Khalifé, Ge Song, Elizabeth R. Champney, Daniel W. Mielcarz, James C. Geoghegan, Dennis R. Burton et al. · 2023 · Nature Communications
36. Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients
    Jira Chansaenroj, Ritthideach Yorsaeng, Nawarat Posuwan, Jiratchaya Puenpa, N. Wanlapakorn, N. Sudhinaraset, M. Sripramote, Piti Chalongviriyalert, Supunee Jirajariyavej, P. Kiatpanabhikul et al. · 2021 · Scientific Reports
37. An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory
    O. Haabeth, J. Lohmeyer, Adrienne Sallets, Timothy R. Blake, Idit Sagiv-Barfi, D. Czerwinski, Blaine G. McCarthy, Abigail E. Powell, P. Wender, R. Waymouth et al. · 2021 · bioRxiv
38. Guardians of the oral and nasopharyngeal galaxy: IgA and protection against SARS‐CoV ‐2 infection*
    Salma Sheikh‐Mohamed, Erin C. Sanders, Jennifer L. Gommerman, Michal Caspi Tal · 2022 · Immunological Reviews
39. Golden Syrian hamster as a model to study cardiovascular complications associated with SARS-CoV-2 infection
    Zaigham Abbas Rizvi, Rajdeep Dalal, Srikanth Sadhu, Akshay Binayke, Jyotsna Dandotiya, Yashwant Kumar, Tripti Shrivastava, Sonu Kumar Gupta, Suruchi Aggarwal, Manas Ranjan Tripathy et al. · 2022 · eLife
40. Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse
    Yingying Du, Yu-Hua Xu, Jin Feng, Longbo Hu, Ya-Nan Zhang, Bo Zhang, Weili Guo, Runming Mai, Li-Yun Chen, Jianmin Fang et al. · 2021 · Vaccine
41. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice
    Alexander A. Cohen, Priyanthi N.P. Gnanapragasam, Yu Erica Lee, Pauline R. Hoffman, Susan Ker-hwa Ou, Leesa M. Kakutani, Jennifer R. Keeffe, Hung‐Jen Wu, Mark R. Howarth, Anthony P. West et al. · 2021 · Science
42. Effective high-throughput isolation of fully human antibodies targeting infectious pathogens
    L. Gieselmann, C. Kreer, M. Ercanoglu, Nathalie Lehnen, Matthias Zehner, P. Schommers, Julian Potthoff, H. Gruell, F. Klein · 2021 · Nature Protocols
43. Correlates of Vaccine-Induced Protection against SARS-CoV-2
    Till Koch, Sibylle C. Mellinghoff, Parichehr Shamsrizi, Marylyn M. Addo, Christine Dahlke · 2021 · Vaccines
44. A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants
    Aaron J. Schmitz, J. Turner, Zhuo-Ming Liu, Julian Q. Zhou, Ishmael D. Aziati, Rita E. Chen, Astha Joshi, T. Bricker, Tamarand L. Darling, Daniel C. Adelsberg et al. · 2021 · Immunity
45. Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry
    Chuan Xu, Annie Wang, M. Marin, W. Honnen, Santhamani Ramasamy, E. Porter, S. Subbian, A. Pinter, G. Melikyan, Wu-Yuan Lu et al. · 2021 · Viruses
46. Shared B cell memory to coronaviruses and other pathogens varies in human age groups and tissues
    Fan Yang, Sandra C. A. Nielsen, R. Hoh, K. Röltgen, O. Wirz, Emily Haraguchi, Grace H. Jean, Ji-Yeun Lee, T. Pham, K. Jackson et al. · 2020 · Science
47. A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike
    M. Claireaux, T. Caniels, Marlon de Gast, Julianna Han, Denise Guerra, G. Kerster, B. V. van Schaik, A. Jongejan, A. Schriek, M. Grobben et al. · 2022 · Nature Communications
48. Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses
    B. B. Banach, G. Cerutti, A. Fahad, Chen-Hsiang Shen, Matheus Oliveira de Souza, P. Katsamba, Y. Tsybovsky, Pengfei Wang, M. Nair, Yao-Xing Huang et al. · 2021 · Cell Reports
49. Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma
    William N. Voss, Y. Hou, N. Johnson, Jin Eyun Kim, George Delidakis, Andrew P. Horton, Foteini Bartzoka, Chelsea J. Paresi, Yuri Tanno, Shawn A. Abbasi et al. · 2020 · bioRxiv
50. Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
    Liu, Jun, Budylowski, Patrick, Samson, Reuben, Griffin, Bryan D., Babuadze, Giorgi, Rathod, Bhavisha, Colwill, Karen, Abioye, Jumai A., Schwartz, Jordan A., Law, Ryan et al. · 2022 · Science Advances
51. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients
    Ioannis P. Trougakos, Evangelos Terpos, Christina Zirou, Aimilia D. Sklirou, Filia Apostolakou, Sentiljana Gumeni, Ioanna Charitaki, Eleni‐Dimitra Papanagnou, Tina Bagratuni, Christine‐Ivy Liacos et al. · 2021 · BMC Medicine
52. A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site
    T. Onodera, S. Kita, Yu Adachi, Saya Moriyama, A. Sato, T. Nomura, S. Sakakibara, Takeshi Inoue, T. Tadokoro, Y. Anraku et al. · 2021 · Immunity
53. In Search of the SARS-CoV-2 Protection Correlate: Head-to-Head Comparison of Two Quantitative S1 Assays in Pre-characterized Oligo-/Asymptomatic Patients
    R. Rubio-Acero, N. Castelletti, V. Fingerle, Laura Olbrich, A. Bakuli, R. Wölfel, P. Girl, Katharina Müller, S. Jochum, M. Strobl et al. · 2021 · Infectious Disease and Therapy
54. COVID-19 neutralizing antibodies predict disease severity and survival
    W. Garcia-Beltran, E. Lam, M. Astudillo, Diane Yang, T. Miller, J. Feldman, B. Hauser, Timothy M. Caradonna, K. Clayton, Adam D. Nitido et al. · 2020 · Cell
55. Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail
    Dong, Jinhui, Zost, Seth J., Greaney, Allison J., Starr, Tyler N., Dingens, Adam S., Chen, Elaine C., Chen, Rita E., Case, James Brett, Sutton, Rachel E., Gilchuk, Pavlo et al. · 2021
56. Role of Senescence and Aging in SARS-CoV-2 Infection and COVID-19 Disease
    Seodhna M. Lynch, Guangran Guo, David S. Gibson, Anthony J. Bjourson, Taranjit Singh · 2021 · Cells
57. Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals
    A. Markmann, Natasa Giallourou, D. Bhowmik, Y. Hou, A. Lerner, David R. Martinez, L. Premkumar, H. Root, D. van Duin, S. Napravnik et al. · 2021 · Msphere
58. Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers
    E. Rujas, I. Kucharska, Yong-Zi Tan, S. Benlekbir, H. Cui, Tian-Tian Zhao, G. Wasney, P. Budylowski, Furkan Guvenc, J. Newton et al. · 2021 · Nature Communications
59. Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies
    C. A. Jette, Alexander A. Cohen, Priyanthi N. P. Gnanapragasam, Frauke Muecksch, Y. Lee, Kathryn E. Huey-Tubman, Fabian Schmidt, T. Hatziioannou, P. Bieniasz, M. Nussenzweig et al. · 2021 · bioRxiv
60. SARS-CoV-2 Infection and Lung Regeneration
    Fuxiaonan Zhao, Qingwen Ma, Qing Yue, Huaiyong Chen · 2022 · Clinical Microbiology Reviews
61. Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers
    Kanika Vanshylla, Chengcheng Fan, Marie Wunsch, Nareshkumar Poopalasingam, Matthijs Meijers, Christoph Kreer, Franziska Kleipass, Denis Ruchnewitz, Meryem Seda Ercanoglu, Henning Gruell et al. · 2021 · Cell Host & Microbe
62. Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine
    Kevin J. Kramer, E. Wilfong, Kelsey Voss, Sierra M. Barone, Andrea R. Shiakolas, Nagarajan Raju, Caroline E. Roe, Naveenchandra Suryadevara, Lauren M. Walker, Steven C. Wall et al. · 2021 · Nature Communications
63. CD38 in the age of COVID-19: a medical perspective
    A. Horenstein, A. Faini, F. Malavasi · 2021 · Physiological Reviews
64. Expression and characterization of SARS-CoV-2 spike proteins
    Jeffrey M. Schaub, Chia-Wei Chou, Hung-Che Kuo, Kamyab Javanmardi, Ching-Lin Hsieh, J. Goldsmith, Andrea M. DiVenere, Kevin C. Le, D. Wrapp, P. O. Byrne et al. · 2021 · Nature Protocols
65. Cross-reactive antibodies against human coronaviruses and the animal coronavirome suggest diagnostics for future zoonotic spillovers
    S. Klompus, S. Leviatan, T. Vogl, R. Mazor, I. Kalka, Liat Stoler-Barak, Nachum Nathan, Ayelet Peres, L. Moss, A. Godneva et al. · 2021 · Science immunology
66. Development and application of therapeutic antibodies against COVID-19
    Lin-jin Ning, H. B. Abagna, Qianhu Jiang, Siqi Liu, Jian Huang · 2021 · International Journal on Biological Sciences
67. Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications
    Endeshaw Chekol Abebe, Tadesse Asmamaw Dejenie · 2023 · Frontiers in Immunology
68. Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
    Jun Liu, P. Budylowski, R. Samson, B. Griffin, G. Babuadze, B. Rathod, Karen Colwill, J. Abioye, J. Schwartz, R. Law et al. · 2021 · bioRxiv
69. Nicotinic cholinergic system and COVID-19: In silico identification of interactions between α7 nicotinic acetylcholine receptor and the cryptic epitopes of SARS-Co-V and SARS-CoV-2 Spike glycoproteins
    George Lagoumintzis, Christos T. Chasapis, N. Alexandris, D. Kouretas, S. Tzartos, E. Eliopoulos, K. Farsalinos, K. Poulas · 2021 · Food and Chemical Toxicology
70. Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11
    J. Fedry, Daniel L. Hurdiss, Chunyan Wang, Wen-Tao Li, G. Obal, I. Drulyte, Wenjuan Du, S. Howes, F. V. van Kuppeveld, Friedrich G. Förster et al. · 2021 · Science Advances
71. Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses
    Sham Nambulli, Yufei Xiang, N. L. Tilston-Lunel, L. Rennick, Z. Sang, W. Klimstra, D. Reed, N. Crossland, Yi Shi, W. P. Duprex · 2021 · bioRxiv
72. Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses to SARS-CoV-2 in mild or moderate non-hospitalised patients
    A. Cook, S. Faustini, L. Williams, A. Cunningham, M. Drayson, A. Shields, Dale Kay, L. Taylor, T. Plant, A. Huissoon et al. · 2020 · medRxiv
73. Identification of a conserved S2 epitope present on spike proteins from all highly pathogenic coronaviruses
    Rui P. Silva, Yimin Huang, Annalee W. Nguyen, Ching-Lin Hsieh, O. S. Olaluwoye, Tamer S. Kaoud, Rebecca Wilen, Ahlam N. Qerqez, Jun-Gyu Park, A. Khalil et al. · 2023 · eLife
74. Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes
    Chengcheng Fan, Alexander A. Cohen, Miso Park, Alfur Fu-Hsin Hung, Jennifer R. Keeffe, Priyanthi N.P. Gnanapragasam, Yu Erica Lee, Han Gao, Leesa M. Kakutani, Ziyan Wu et al. · 2022 · Immunity
75. Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses
    Wanting He, Rami Ghassan Musharrafieh, Ge Song, Katharina Dueker, Longping V. Tse, David R. Martinez, Alexandra Schäfer, Sean Callaghan, Peter Yong, Nathan Beutler et al. · 2022 · Nature Immunology
76. Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain
    A. Wheatley, P. Pymm, R. Esterbauer, M. Dietrich, W. Lee, D. Drew, Hannah G. Kelly, L. Chan, F. Mordant, K. A. Black et al. · 2021 · Cell Reports
77. Tackling COVID-19 with neutralizing monoclonal antibodies
    Davide Corti, Lisa A. Purcell, Gyorgy Snell, David Veesler · 2021 · Cell
78. Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals
    Elaine C. Chen, P. Gilchuk, Seth J. Zost, Naveenchandra Suryadevara, Emma S. Winkler, C. R. Cabel, E. Binshtein, Rachel E. Sutton, Jessica L. Rodriguez, Samuel B. Day et al. · 2021 · bioRxiv
79. Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2
    Huihui Mou, Brian D. Quinlan, Haiyong Peng, Guanqun Liu, Yan Guo, Shoujiao Peng, Lizhou Zhang, Meredith E. Davis-Gardner, Matthew R. Gardner, Gogce C. Crynen et al. · 2021 · PLoS Pathogens
80. Nanotraps for the containment and clearance of SARS-CoV-2
    Min Chen, Jillian Rosenberg, Xiaolei Cai, A. Lee, Jiu-Yun Shi, Mindy Nguyen, T. Wignakumar, Vikranth R. Mirle, Arianna Edobor, John F. Fung et al. · 2021 · bioRxiv
81. SARS-CoV-2-Associated T-Cell Responses in the Presence of Humoral Immunodeficiency
    Sudhir Gupta, Houfen Su, Tejal Narsai, Sudhanshu Agrawal · 2021 · International Archives of Allergy and Immunology
82. Neutralizing monoclonal antibodies for COVID-19 treatment and prevention
    J. Jaworski · 2020 · Biomedical Journal
83. Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19
    Ting Lu, Rui Ma, Wen-Juan Dong, Kun-Yu Teng, Daniel S. Kollath, Zhi-Yao Li, Jinhee Yi, C. Bustillos, Shou-Bao Ma, L. Tian et al. · 2022 · Nature Communications
84. Modeling how antibody responses may determine the efficacy of COVID-19 vaccines
    Pranesh Padmanabhan, Rajat Desikan, Narendra M. Dixit · 2022 · Nature Computational Science
85. Dynamics of B cell repertoires and emergence of cross-reactive responses in patients with different severities of COVID-19
    Zachary Montague, Huibin Lv, J. Otwinowski, William S. DeWitt, G. Isacchini, Garrick K. Yip, Wilson W. Ng, O. Tsang, M. Yuan, Hejun Liu et al. · 2021 · Cell Reports
86. NeutrobodyPlex—monitoring SARS-CoV-2 neutralizing immune responses using nanobodies
    Teresa R. Wagner, Philipp D. Kaiser, Marius Gramlich, Elena Ostertag, Natalia Ruétalo, Daniel Junker, Julia Häring, Bjoern Traenkle, Matthias Becker, Alex Dulovic et al. · 2021 · EMBO Reports
87. Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors
    M. Mor, M. Werbner, J. Alter, Modi Safra, Elad Chomsky, J. C. Lee, Smadar Hada-Neeman, Ksenia Polonsky, C. Nowell, A. Clark et al. · 2021 · PLoS Pathogens
88. SARS-CoV-2: vaccines in the pandemic era
    Dan Li, Qi-Han Li · 2021 · Military Medical Research
89. Pattern of circulating SARS‐CoV‐2‐specific antibody‐secreting and memory B‐cell generation in patients with acute COVID‐19
    Maria G. Byazrova, Gaukhar M. Yusubalieva, Anna A. Spiridonova, Grigory Aleksandrovich Efimov, Dmitriy V. Mazurov, Konstantin O. Baranov, Vladimir P. Baklaushev, Alexander V. Filatov · 2021 · Clinical & Translational Immunology
90. Immunoglobulin germline gene polymorphisms influence the function of SARS-CoV-2 neutralizing antibodies
    Pradeepa Pushparaj, Andrea Nicoletto, D. Sheward, H. Das, X. C. Dopico, Laura Perez Vidakovics, L. Hanke, M. Chernyshev, Sanjana Narang, Sungyong Kim et al. · 2022 · Immunity
91. COVID‐19 immunopathology: From acute diseases to chronic sequelae
    Mohd Arish, Wei Guo Qian, Harish Narasimhan, Jie Sun · 2022 · Journal of Medical Virology
92. Efficient discovery of SARS-CoV-2-neutralizing antibodies via B-cell receptor sequencing and ligand blocking
    Andrea R. Shiakolas, Kevin J. Kramer, N. Johnson, Steven C. Wall, Naveenchandra Suryadevara, D. Wrapp, S. Periasamy, Kelsey A. Pilewski, Nagarajan Raju, Rachel S. Nargi et al. · 2022 · Nature Biotechnology
93. A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection
    Hejun Liu, M. Yuan, De-Li Huang, S. Bangaru, Fang-Zhu Zhao, C. D. Lee, Linghang Peng, Shawn Barman, Xue-Yong Zhu, D. Nemazee et al. · 2021 · Cell Host and Microbe
94. Epitope profiling using computational structural modelling demonstrated on coronavirus-binding antibodies
    Robinson, Sarah A., Raybould, Matthew I. J., Schneider, Constantin, Wong, Wing Ki, Marks, Claire, Deane, Charlotte M. · 2021 · PLOS Computational Biology
95. Protective neutralizing epitopes in SARS‐CoV‐2
    Hejun Liu, Ian A. Wilson · 2022 · Immunological Reviews
96. Complete protection by a single-dose skin patch–delivered SARS-CoV-2 spike vaccine
    Christopher L. D. McMillan, J. J. Choo, A. Idris, Aroon Supramaniam, N. Modhiran, A. Amarilla, Ariel Isaacs, Stacey T M Cheung, Benjamin Liang, H. Bielefeldt-Ohmann et al. · 2021 · bioRxiv
97. Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment
    Norma A. Valdez-Cruz, E. García-Hernández, C. Espitia, L. Cobos-Marín, C. Altamirano, Carlos G. Bando-Campos, L. F. Cofas-Vargas, E. W. Coronado-Aceves, Ricardo A. González-Hernández, Pablo Hernández-Peralta et al. · 2021 · Microbial Cell Factories
98. Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients
    Q. Yan, P. He, Xiaohan Huang, K. Luo, Yu-Di Zhang, Haisu Yi, Qian Wang, Feng Li, Rui-Tian Hou, Xiaodi Fan et al. · 2021 · Emerging Microbes and Infections
99. Variations within the Glycan Shield of SARS-CoV-2 Impact Viral Spike Dynamics
    M. Newby, C. Fogarty, J. Allen, J. Butler, E. Fadda, M. Crispin · 2022 · Journal of Molecular Biology
100. A neutralizing epitope on the SD1 domain of SARS-CoV-2 spike targeted following infection and vaccination
     J. Seow, Hataf Khan, Annachiara Rosa, Valeria Calvaresi, C. Graham, S. Pickering, V. E. Pye, N. Cronin, I. Huettner, M. Malim et al. · 2022 · Cell Reports